XML 41 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies - Narrative (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Sep. 30, 2022
USD ($)
day
shares
Sep. 30, 2021
USD ($)
Oct. 23, 2022
$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of operating segments | day 1    
Number of reporting segments | day 1    
Amortization of operating lease right-of-use assets $ 935 $ 820  
Cash, cash equivalents and marketable securities $ 371,300    
Subsequent Event | Sumitomo Pharma, Co., Ltd. | Myovant Sciences Ltd.      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Share price (in USD per share) | $ / shares     $ 27.00
Sumitomo Pharma, Co., Ltd. | Majority Shareholder      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of shares owned (in shares) | shares 50,041,181    
Ownership percentage 51.80%    
Sumitomo Pharma, Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan | Majority Shareholder      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Available borrowing capacity $ 41,300    
Richter      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Outstanding payment from milestones achieved 122,200    
Accord Healthcare, Ltd | Accord license revenue      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Additional milestone payments eligible to receive $ 90,500